Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Skeletal > Skeletal Osteogenesis Imperfecta

Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI) is a disorder of bone fragility caused generally by mutations in the COL1A1 and COL1A2 genes that encode type I collagen. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Osteogenesis Imperfecta (OI) is a disorder of bone fragility caused generally by mutations in the COL1A1 and COL1A2 genes that encode type I collagen. OI is one of the most common skeletal dysplasias. It is a generalized disease that is phenotypically and molecularly heterogeneous manifesting with a broad array of signs and symptoms including connective tissue and systemic manifestations in addition to bone fragility. 

  • The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type 1 collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type 1 procollagen. There are at least 8 different types of the disease based on the inheritance. The differential diagnosis of OI includes child abuse, rickets, osteomalacia and other rare skeletal syndromes.  

  • The Igenomix Osteogenesis Imperfecta Precision Panel can be used to make a directed and accurate differential diagnosis of bone fragility ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

The Igenomix Osteogenesis Imperfecta Precision Panel is indicated for those patients with a suspected clinical diagnosis of osteogenesis imperfecta presenting with the following manifestations: 

  • Blue sclerae 
  • Triangular facies 
  • Macrocephaly 
  • Hearing loss 
  • Defective dentition 
  • Barrel chest 
  • Scoliosis 
  • Limb deformities 
  • Pregnancy ultrasound: Limb-length abnormalities at 15-18 weeks’ gestation, decreased mineralization of calvaria, bowing of the long bones, multiple rib fractures 
  • Fractures 
  • Joint laxity 
  • Growth retardation 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team, encompassing physical rehabilitation and surgical procedures, management of hearing, dental and pulmonary abnormalities, as well as drugs, such as bisphosphonates and recombinant human growth hormone.  
  • Prenatal detection of osteogenesis imperfecta for a directed obstetric and perinatal treatment of affected infants. 
  • Combining phenotypic and genotypic data to improve diagnostic rate of these patients in the target population.  
  • Risk assessment of asymptomatic family members according to the mode of inheritance

Genes & Diseases

Methodology

References

See scientific referrals

Pauli, R. (2019). Achondroplasia: a comprehensive clinical review. Orphanet Journal Of Rare Diseases, 14(1). doi: 10.1186/s13023-018-0972-6 

Horton, W., Hall, J., & Hecht, J. (2007). Achondroplasia. The Lancet, 370(9582), 162-172. doi: 10.1016/s0140-6736(07)61090-3 

Baitner, A., Maurer, S., Gruen, M., & Di Cesare, P. (2000). The Genetic Basis of the Osteochondrodysplasias. Journal Of Pediatric Orthopaedics, 594-605. doi: 10.1097/00004694-200009000-00010 

Ornitz, D. M., & Legeai-Mallet, L. (2017). Achondroplasia: Development, pathogenesis, and therapy. Developmental dynamics : an official publication of the American Association of Anatomists, 246(4), 291–309. https://doi.org/10.1002/dvdy.24479 

Daugherty A. (2017). Achondroplasia: Etiology, Clinical Presentation, and Management. Neonatal network : NN, 36(6), 337–342. https://doi.org/10.1891/0730-0832.36.6.337 

Horton, W., Hall, J., & Hecht, J. (2007). Achondroplasia. The Lancet, 370(9582), 162-172. doi: 10.1016/s0140-6736(07)61090-3 

Legare JM. Achondroplasia. 1998 Oct 12 [Updated 2020 Aug 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1152/ 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information